Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Takayuki Yoshino(University of Tsukuba), Kojiro Kobayashi(Daiichi Sankyo (United States)), Marc Van den Eynde(Cliniques Universitaires Saint-Luc), Atsuo Takashima(National Cancer Center Hospital East), Marc Peeters(Ghent University Hospital), Salvatore Siena(University of Milan), Sara Lonardi(Istituto Oncologico Veneto), Daniel Barrios(Daiichi Sankyo (United States)), Yoshito Komatsu(Hokkaido University Hospital), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Jeanne Tie(University of Melbourne), Thierry André(Sorbonne Université), Kensei Yamaguchi(The Cancer Institute Hospital), Takeshi Kato(Osaka National Hospital), Qi Yan(Wuhan University), Takahiro Kamio(Daiichi Sankyo (United States)), John H. Strickler(Duke Medical Center), Cristina Grávalos Castro(Research Institute Hospital 12 de Octubre), Hisato Kawakami(Kindai University)
Cited by 77
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k